SAN FRANCISCO--(BUSINESS WIRE)--Castlight Health®, Inc. (NYSE:CSLT), a pioneer of the Enterprise Healthcare Cloud, today announced results for its second quarter ended June 30, 2014.
“Demand for Castlight’s Enterprise Healthcare Cloud remains strong as large organizations are increasingly evaluating enterprise healthcare technology to gain control of their healthcare spending,” said Giovanni Colella, M.D., co-founder and Chief Executive Officer of Castlight Health. “We ended the second quarter with 130 customers and expanded our Fortune 500 customer list by more than 20 percent. New large customers included Google, Kellogg Company, Texas Instruments and Sprint Corporation, among others. Further, we continue to execute well. We launched 13 additional customers during the second quarter, including CalPERS, and implemented Castlight Pharmacy and Castlight Rewards for 12 existing customers.”
Colella continued, “We continue to launch new products and lead the way with technologies that enable innovative benefit designs for our customers. We were pleased to announce the upcoming launch of Castlight Dental, which is the newest significant expansion of our Castlight Care Solution Center alongside Castlight Medical and Castlight Pharmacy.”
Financial Performance for the Three Months Ended June 30, 2014
- Total revenue for the second quarter of 2014 was $10.5 million, an increase of 353% from the second quarter of 2013. Subscription revenue was $9.6 million, an increase of 359% on a year-over-year basis. Professional services revenue was $1.0 million, an increase of 304% compared with the same period last year.
- Gross margin for the second quarter of 2014 was 29.6%, compared to a gross loss of 64.9% in the second quarter of 2013. Non-GAAP gross margin for the second quarter of 2014 was 32.6% compared to a gross loss of 63.9% in the second quarter of 2013.
- Operating loss for the second quarter of 2014 was $21.8 million, compared to an operating loss of $14.2 million during the second quarter of 2013. Non-GAAP operating loss for the second quarter of 2014 was $18.8 million, compared to a non-GAAP operating loss of $13.7 million during the second quarter of 2013.
- Net loss per basic and diluted share was ($0.24) in the second quarter of 2014, compared to a loss of ($1.47) per share in the second quarter of 2013. The non-GAAP net loss per share for the second quarter of 2014 was ($0.21), compared to a loss of ($1.43) per share in the second quarter of 2013. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the second quarter of 2014 was 89.5 million compared to 9.6 million in the second quarter of 2013.
- Total cash, cash equivalents and marketable securities were $217.9 million at the end of the second quarter of 2014, compared to $239.7 million at the end of last quarter. Cash used in operations for the second quarter of 2014 was $19.6 million, compared to $16.1 million used in operations last quarter.
A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.
Business Outlook
Q3 2014 Guidance: Revenue for the company’s third fiscal quarter is expected to be in the range of $11.3 million to $11.6 million, an increase of 214% to 222% year-over-year. Non-GAAP operating loss is expected to be in the range of ($18.7) million to ($19.0) million. Non-GAAP basic and diluted loss per share is expected to be approximately ($0.21) based on 90.0 million weighted average basic and diluted common shares outstanding.
Full Year 2014 Guidance: Revenue for the company’s full year 2014 is expected to be in the range of $42.6 million to $43.2 million, an increase of 228% to 232% year-over- year. Non-GAAP operating loss is expected to be in the range of ($75.0) million to ($76.0) million. Non-GAAP basic and diluted loss per share is expected to be in the range of ($1.00) to ($1.01) based on 75.0 million weighted average basic and diluted common shares outstanding.
For both the third quarter and the full year 2014, non-GAAP estimates exclude the effects of stock-based compensation expense and warrant expense.
Leadership Updates
Castlight Health announced today that Randy Womack, chief operating officer, will step down September 30, 2014 after nearly four years of service with the company. Mr. Womack’s responsibilities will be assumed by other members of Castlight’s management team after a seamless transition process is completed.
Additionally, Concur CEO Steve Singh has joined Castlight’s Board of Directors, effective immediately. Concurrently, directors Bob Kocher, M.D., partner at Venrock, and Christopher P. Michel, managing director at Nautilus Ventures, departed the Board. Dr. Kocher will remain as an advisor to the company, and Bryan Roberts, co-founder of Castlight and general partner at Venrock, remains Castlight’s Chairman of the Board. These changes follow the April addition of Ed Park, executive vice president and chief operating officer of athenahealth to the Board of Directors.
“We would like to thank Randy for his efforts to help make Castlight such a great company and achieve such strong momentum as a business. Randy has decided to leave the company with the success of his third IPO to pursue his passion for startups. We wish him every success in his future endeavors,” said Colella. “Moving forward, Castlight has an incredibly strong group of experienced, proven leaders. I look forward to working with them to continue to capture growth and realize innovation opportunities.”
Quarterly Conference Call
Castlight Health will host a conference call to discuss its second quarter results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the audiocast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-201-689-8562. A replay will be available at 1-858-384-5517, passcode 13586458, until midnight (Eastern Time) August 5, 2014.
About Castlight Health
Castlight Health, Inc. (NYSE: CSLT) believes great healthcare builds great business. The Castlight Enterprise Healthcare Cloud enables employers to deliver cost-effective benefits, provides medical professionals and health plans a merit-based market to showcase their services, and – most importantly – empowers employees to make informed choices with a clear understanding of costs and likely outcomes. For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook. Source: Castlight Health.
Non-GAAP Financial Measures
To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin (loss), non-GAAP operating expense, non-GAAP operating loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, expense for a warrant issued to a third-party service provider and the associated tax impact of these items, where applicable.
We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.
We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the third quarter and full fiscal year of 2014 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and warrant expense, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and warrant expense are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.
These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s third quarter and full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.
Copyright 2014 Castlight Health, Inc. Castlight Health, Castlight, Castlight Medical, Castlight Pharmacy, Castlight Dental, Castlight Care Solution Center are trademarks and/or registered trademarks of Castlight Health Inc. in the United States and other countries. Other company and product names may be trademarks of the respective companies with which they are associated.
| CASTLIGHT HEALTH, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands) | ||||||||
| As of | ||||||||
| June 30, | December 31, | |||||||
| 2014 | 2013 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 35,268 | $ | 25,154 | ||||
| Marketable securities | 124,560 | 42,017 | ||||||
| Accounts receivable, net | 10,392 | 5,065 | ||||||
| Deferred commissions | 2,946 | 3,648 | ||||||
| Prepaid expenses and other current assets | 3,010 | 1,583 | ||||||
| Total current assets | 176,176 | 77,467 | ||||||
| Property and equipment, net | 3,164 | 2,631 | ||||||
| Marketable securities, noncurrent | 58,095 | - | ||||||
|
Restricted cash, noncurrent |
- | 101 | ||||||
| Deferred commissions, noncurrent | 1,648 | 1,821 | ||||||
| Other assets | 380 | 1,497 | ||||||
| Total assets | $ | 239,463 | $ | 83,517 | ||||
| Liabilities, convertible preferred stock and stockholders' equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,928 | $ | 2,536 | ||||
| Accrued expenses and other current liabilities | 3,937 | 4,998 | ||||||
| Accrued compensation | 6,984 | 8,064 | ||||||
| Deferred revenue | 13,970 | 6,925 | ||||||
| Total current liabilities | 27,819 | 22,523 | ||||||
| Deferred revenue, noncurrent | 5,780 | 4,548 | ||||||
| Other liabilities, noncurrent | 317 | 373 | ||||||
| Total liabilities | 33,916 | 27,444 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock | - | 180,423 | ||||||
| Stockholders' equity (deficit) | 205,547 | (124,350 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $ | 239,463 | $ | 83,517 | ||||
| CASTLIGHT HEALTH, INC. | |||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||||
| Revenue: | |||||||||||||||||
| Subscription | $ | 9,576 | $ | 2,088 | $ | 17,039 | $ | 3,827 | |||||||||
| Professional services | 957 | 237 | 1,870 | 405 | |||||||||||||
| Total revenue | 10,533 | 2,325 | 18,909 | 4,232 | |||||||||||||
| Cost of revenue: | |||||||||||||||||
| Cost of subscription (1) | 2,915 | 1,460 | 5,627 | 2,664 | |||||||||||||
| Cost of professional services (1) | 4,502 | 2,373 | 8,373 | 4,426 | |||||||||||||
| Total cost of revenue | 7,417 | 3,833 | 14,000 | 7,090 | |||||||||||||
| Gross profit (loss) | 3,116 | (1,508 | ) | 4,909 | (2,858 | ) | |||||||||||
| Operating expenses: | |||||||||||||||||
| Sales and marketing (1) | 14,947 | 7,108 | 31,507 | 12,873 | |||||||||||||
| Research and development (1) | 5,476 | 3,616 | 11,003 | 6,524 | |||||||||||||
| General and administrative (1) | 4,519 | 1,981 | 8,529 | 3,441 | |||||||||||||
| Total operating expenses | 24,942 | 12,705 | 51,039 | 22,838 | |||||||||||||
| Operating loss | (21,826 | ) | (14,213 | ) | (46,130 | ) | (25,696 | ) | |||||||||
| Other income, net | 50 | 40 | 73 | 90 | |||||||||||||
| Net loss | $ | (21,776 | ) | $ | (14,173 | ) | $ | (46,057 | ) | $ | (25,606 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.24 | ) | $ | (1.47 | ) | $ | (0.86 | ) | $ | (2.71 | ) | |||||
| Weighted-average shares used in basic and diluted net loss per share | 89,520 | 9,619 | 53,284 | 9,438 | |||||||||||||
| (1)Includes stock-based compensation expense as follows: | |||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||||
| Cost of revenue: | |||||||||||||||||
| Cost of subscription | $ | 35 | $ | - | $ | 39 | $ | 1 | |||||||||
| Cost of professional services | 280 | 23 | 420 | 52 | |||||||||||||
| Sales and marketing | 1,152 | 225 | 2,326 | 408 | |||||||||||||
| Research and development | 493 | 61 | 914 | 110 | |||||||||||||
| General and administrative | 980 | 156 | 1,794 | 272 | |||||||||||||
| CASTLIGHT HEALTH, INC. | |||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||||
| (In thousands) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||||
| Operating activities: | |||||||||||||||||
| Net loss | $ | (21,776 | ) | $ | (14,173 | ) | $ | (46,057 | ) | $ | (25,606 | ) | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||||
| Depreciation | 322 | 113 | 604 | 213 | |||||||||||||
| Stock-based compensation | 2,940 | 465 | 5,493 | 843 | |||||||||||||
| Amortization of deferred commission | 868 | 196 | 2,244 | 325 | |||||||||||||
| Accretion and amortization of marketable securities | 373 | 193 | 497 | 421 | |||||||||||||
| Expense related to issuance of warrant | 70 | - | 2,499 | - | |||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||
| Accounts receivable | (4,077 | ) | (1,412 | ) | (5,327 | ) | (1,387 | ) | |||||||||
| Deferred commissions | (1,087 | ) | (700 | ) | (1,369 | ) | (1,267 | ) | |||||||||
| Prepaid expenses and other assets | (596 | ) | (435 | ) | (1,677 | ) | (535 | ) | |||||||||
| Accounts payable | (375 | ) | 849 | 384 | 279 | ||||||||||||
| Accrued expenses and other liabilities | 2,173 | 2,406 | (1,203 | ) | 1,109 | ||||||||||||
| Deferred revenue | 1,591 | 2,493 | 8,277 | 3,446 | |||||||||||||
| Net cash used in operating activities | (19,574 | ) | (10,005 | ) | (35,635 | ) | (22,159 | ) | |||||||||
| Investing activities | |||||||||||||||||
| Decrease restricted cash, net | 101 | - | 101 | - | |||||||||||||
| Purchase of property and equipment | (311 | ) | (408 | ) | (967 | ) | (1,118 | ) | |||||||||
| Purchase of marketable securities | (126,442 | ) | (8,382 | ) | (162,175 | ) | (16,480 | ) | |||||||||
| Sales of marketable securities | - | - | 13,000 | 5,000 | |||||||||||||
| Maturities of marketable securities | 3,000 | 39,075 | 8,000 | 44,075 | |||||||||||||
| Net cash (used in) provided by investing activities | (123,652 | ) | 30,285 | (142,041 | ) | 31,477 | |||||||||||
| Financing activities | |||||||||||||||||
| Proceeds from the exercise of stock options | 106 | 154 | 1,628 | 200 | |||||||||||||
| Payments of deferred financing costs | (1,679 | ) | - | (3,781 | ) | - | |||||||||||
|
Net proceeds from initial public offering |
- | - | 189,943 | - | |||||||||||||
| Net cash (used in) provided by financing activities | (1,573 | ) | 154 | 187,790 | 200 | ||||||||||||
| Net increase (decrease) in cash and cash equivalents | (144,799 | ) | 20,434 | 10,114 | 9,518 | ||||||||||||
| Cash and cash equivalents at beginning of the period | 180,067 | 31,618 | 25,154 | 42,534 | |||||||||||||
| Cash and cash equivalents at end of the period | $ | 35,268 | $ | 52,052 | $ | 35,268 | $ | 52,052 | |||||||||
| CASTLIGHT HEALTH, INC. | ||||||||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||||||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||
| June 30, | March 31, | June 30, | June 30, | June 30, | ||||||||||||||||||
| 2014 | 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||
| Gross profit (loss): | ||||||||||||||||||||||
|
GAAP gross profit subscription |
$ | 6,661 | $ | 4,751 | $ | 628 | $ | 11,412 | $ | 1,163 | ||||||||||||
| GAAP gross margin subscription | 69.6 | % | 63.7 | % | 30.1 | % | 67.0 | % | 30.4 | % | ||||||||||||
| Stock-based compensation expense included in cost of revenue subscription | 35 | 4 | - | 39 | 1 | |||||||||||||||||
| Non-GAAP gross profit subscription | $ | 6,696 | $ | 4,755 | $ | 628 | $ | 11,451 | $ | 1,164 | ||||||||||||
| Non-GAAP gross margin subscription | 69.9 | % | 63.7 | % | 30.1 | % | 67.2 | % | 30.4 | % | ||||||||||||
| GAAP gross loss professional services | $ | (3,545 | ) | $ | (2,958 | ) | $ | (2,136 | ) | $ | (6,503 | ) | $ | (4,021 | ) | |||||||
| GAAP gross loss percentage professional services | (370 | ) | % | (324 | ) | % | (901 | ) | % | (348 | ) | % | (993 | ) | % | |||||||
| Stock-based compensation expense included in cost of revenue professional services | 280 | 140 | 23 | 420 | 52 | |||||||||||||||||
| Non-GAAP gross loss professional services | $ | (3,265 | ) | $ | (2,818 | ) | $ | (2,113 | ) | $ | (6,083 | ) | $ | (3,969 | ) | |||||||
| Non-GAAP gross loss percentage professional services | (341 | ) | % | (309 | ) | % | (892 | ) | % | (325 | ) | % | (980 | ) | % | |||||||
| GAAP gross profit (loss) | $ | 3,116 | $ | 1,793 | $ | (1,508 | ) | $ | 4,909 | $ | (2,858 | ) | ||||||||||
| GAAP gross margin (loss percentage) | 29.6 | % | 21.4 | % | (64.9 | ) | % | 26.0 | % | (67.5 | ) | % | ||||||||||
| Impact of non-GAAP adjustments | 315 | 144 | 23 | 459 | 53 | |||||||||||||||||
| Non-GAAP gross profit (loss) | $ | 3,431 | $ | 1,937 | $ | (1,485 | ) | $ | 5,368 | $ | (2,805 | ) | ||||||||||
| Non-GAAP gross margin (loss percentage) | 32.6 | % | 23.1 | % | (63.9 | ) | % | 28.4 | % | (66.3 | ) | % | ||||||||||
| Operating expense: | ||||||||||||||||||||||
| GAAP sales and marketing | $ | 14,947 | $ | 16,560 | $ | 7,108 | $ | 31,507 | $ | 12,873 | ||||||||||||
| Expense related to warrant | (70 | ) | (2,429 | ) | - | (2,499 | ) | - | ||||||||||||||
| Stock-based compensation expense included in sales and marketing | (1,152 | ) | (1,174 | ) | (225 | ) | (2,326 | ) | (408 | ) | ||||||||||||
| Non-GAAP sales and marketing | $ | 13,725 | $ | 12,957 | $ | 6,883 | $ | 26,682 | $ | 12,465 | ||||||||||||
| GAAP research and development | $ | 5,476 | $ | 5,527 | $ | 3,616 | $ | 11,003 | $ | 6,524 | ||||||||||||
| Stock-based compensation expense included in research and development | (493 | ) | (421 | ) | (61 | ) | (914 | ) | (110 | ) | ||||||||||||
| Non-GAAP research and development | $ | 4,983 | $ | 5,106 | $ | 3,555 | $ | 10,089 | $ | 6,414 | ||||||||||||
| GAAP general and administrative | $ | 4,519 | $ | 4,010 | $ | 1,981 | $ | 8,529 | $ | 3,441 | ||||||||||||
| Stock-based compensation expense included in general and administrative | (980 | ) | (814 | ) | (156 | ) | (1,794 | ) | (272 | ) | ||||||||||||
| Non-GAAP general and administrative | $ | 3,539 | $ | 3,196 | $ | 1,825 | $ | 6,735 | $ | 3,169 | ||||||||||||
| GAAP operating expenses | $ | 24,942 | $ | 26,097 | $ | 12,705 | $ | 51,039 | $ | 22,838 | ||||||||||||
| Impact of non-GAAP adjustments | (2,695 | ) | (4,838 | ) | (442 | ) | (7,533 | ) | (790 | ) | ||||||||||||
| Non-GAAP operating expenses | $ | 22,247 | $ | 21,259 | $ | 12,263 | $ | 43,506 | $ | 22,048 | ||||||||||||
| Operating loss: | ||||||||||||||||||||||
| GAAP operating loss | $ | (21,826 | ) | $ | (24,304 | ) | $ | (14,213 | ) | $ | (46,130 | ) | $ | (25,696 | ) | |||||||
| Impact of non-GAAP adjustments | 3,010 | 4,982 | 465 | 7,992 | 843 | |||||||||||||||||
| Non-GAAP operating loss | $ | (18,816 | ) | $ | (19,322 | ) | $ | (13,748 | ) | $ | (38,138 | ) | $ | (24,853 | ) | |||||||
| Net loss and net loss per share: | ||||||||||||||||||||||
| GAAP net loss | $ | (21,776 | ) | $ | (24,281 | ) | $ | (14,173 | ) | $ | (46,057 | ) | $ | (25,606 | ) | |||||||
| Total pre-tax impact of non-GAAP adjustments | 3,010 | 4,982 | 465 | 7,992 | 843 | |||||||||||||||||
| Income tax impact of non-GAAP adjustments | - | - | - | - | - | |||||||||||||||||
| Non-GAAP net loss | $ | (18,766 | ) | $ | (19,299 | ) | $ | (13,708 | ) | $ | (38,065 | ) | $ | (24,763 | ) | |||||||
| Basic and Diluted net loss per share | ||||||||||||||||||||||
| GAAP | $ | (0.24 | ) | $ | (0.90 | ) | $ | (1.47 | ) | $ | (0.86 | ) | $ | (2.71 | ) | |||||||
| Non-GAAP | $ | (0.21 | ) | $ | (0.72 | ) | $ | (1.43 | ) | $ | (0.71 | ) | $ | (2.62 | ) | |||||||
| Shares used in basic and diluted net loss per share computation | 89,520 | 26,970 | 9,619 | 53,284 | 9,438 | |||||||||||||||||
| Free Cash Flow | ||||||||||||||||||||||
| GAAP net cash flow used in operating activities | $ | (19,574 | ) | $ | (16,061 | ) | $ | (10,005 | ) | $ | (35,635 | ) | $ | (22,159 | ) | |||||||
| Purchase of property and equipment | (311 | ) | (656 | ) | (408 | ) | (967 | ) | (1,118 | ) | ||||||||||||
| Free cash flow | $ | (19,885 | ) | $ | (16,717 | ) | $ | (10,413 | ) | $ | (36,602 | ) | $ | (23,277 | ) | |||||||
